All In Biotech

Drug Trial Radar · NCT07479797

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

May 22, 2026

Primary completion

May 2031

Study completion May 2031

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.

Conditions

  • Relapsed or Refractory Large B-cell Lymphoma

Interventions

  • KITE-753Drug

    A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

  • Axicabtagene CiloleucelDrug

    A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

  • FludarabineDrug

    Administered intravenously

  • CyclophosphamideDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants in Complete Response (CR) at Month 6Time frame: Month 6
  2. Event-free survival (EFS)Time frame: Up to 36 months

Locations

42 sites in 9 countries. Site status is shown where the registry gives one.

  • City of Hope Arizona

    Goodyear, Arizona

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California

  • Stanford University

    Stanford, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Moffitt Cancer Center

    Tampa, Florida

  • Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta

    Newnan, Georgia

  • University of Illinois

    Chicago, Illinois

  • City of Hope - Chicago

    Zion, Illinois

  • University of Maryland St. Joseph Medical Center

    Baltimore, Maryland

  • Washington University

    St Louis, Missouri

  • Weill Cornell Medicine-NewYork-Presbyterian Hospital

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Novant Health Cancer Institute - Hematology

    Charlotte, North Carolina

  • Henry-Joyce Cancer Clinic

    Nashville, Tennessee

  • Tennessee Oncology, PLLC - Investigational Drug Services

    Nashville, Tennessee

  • St. David's South Austin Medical Center

    Austin, Texas

  • Inova Shar Cancer Institute

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • West Virginia University

    Morgantown, West Virginia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Concord Repatriation General Hospital

    Sydney, New South Wales, Australia

  • Epworth Healthcare

    East Melbourne, Victoria, Australia

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Jewish General Hospital

    Montreal, Canada

  • McGill University Health Centre

    Montreal, Canada

  • CHU de Québec, Hôpital de l'Enfant-Jésus

    Québec, Canada

  • Hopital Saint Eloi

    Montpellier, France

  • Universitatsklinikum Wurzburg

    Würzburg, Germany

  • National Cancer Center Hospital

    Tokyo, Japan

  • Toranomon Hospital

    Tokyo, Japan

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Institut Catala d'Oncologia

    Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Cardiff and Vale University Health Board

    Cardiff, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.